Bristol Myers Squibb has expanded its push into radiopharmaceuticals by licensing a prostate cancer therapy developed by Swiss biotech Philochem in a deal that includes an upfront payment of $350 ...
Bristol-Myers Squibb has claimed its second FDA approval in the space of a few days for its immuno-oncology combination of Opdivo and Yervoy, this time in newly diagnosed liver cancer. PD-1 inhibitor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results